EN
登录

VedaBio任命BioFire Diagnostics前首席执行官Randy Rasmussen为董事会成员

VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors

businesswire 等信源发布 2024-10-01 17:00

可切换为仅中文


SAN DIEGO--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors. Dr. Rasmussen, a visionary in the molecular diagnostics field with over 30 years of experience, brings deep industry knowledge to VedaBio as the company advances its breakthrough platform and enters the crucial stage of product development.

圣地亚哥--(商业新闻短讯)--位于分子检测前沿的开创性生物技术公司VedaBio今天宣布任命RandyRasmussen博士为董事会成员。。

In addition to his board position, Dr. Rasmussen will also serve as an Advisor to the company..

除了董事会职位外,拉斯穆森博士还将担任公司顾问。。

'We are honored to welcome Randy to our Board,' said Frédéric Sweeney, Ph.D., President and CEO of VedaBio. 'Having worked with Randy in the past, I know firsthand the depth of his expertise and strategic insight. His leadership in molecular diagnostics and ability to scale innovation into commercial success make him an invaluable partner as we move into the next phase of our journey.'.

韦达比奥总裁兼首席执行官弗里德·德里克·斯威尼博士说:“我们很荣幸欢迎兰迪加入我们的董事会。过去曾与兰迪合作过,我亲身了解到他的专业知识和战略见解的深度。他在分子诊断方面的领导才能以及将创新扩展到商业成功的能力,使他成为我们进入旅程下一阶段的宝贵合作伙伴。”。

Dr. Rasmussen co-founded Idaho Technology, later rebranded as BioFire Diagnostics, where he held the roles of President, COO, and ultimately CEO. Under his leadership, BioFire Diagnostics became a transformative force in molecular diagnostics, particularly with its pioneering approach to syndromic testing for infectious diseases.

拉斯穆森博士是爱达荷州科技公司的联合创始人,后来更名为BioFire Diagnostics,担任总裁、首席运营官,最终担任首席执行官。在他的领导下,BioFire Diagnostics成为分子诊断领域的变革力量,特别是其开创性的传染病综合征检测方法。

During his tenure, the company grew to over 3,000 employees and exceeded $1 billion in revenue. BioFire was acquired by bioMérieux in 2013, where Dr. Rasmussen served as CEO of the subsidiary until his retirement in 2020. He holds a Bachelor of Science in Biochemistry from Utah State University and a Ph.D.

在他的任期内,该公司的员工人数增加到3000多名,收入超过10亿美元。BioFire于2013年被bioMérieux收购,Rasmussen博士担任该子公司的首席执行官,直到2020年退休。他拥有犹他州立大学生物化学学士学位和博士学位。

in Molecular Biology from the University of Utah..

犹他大学分子生物学专业。。

'I am thrilled to join VedaBio at such a pivotal time,' said Dr. Rasmussen. 'The company's technology and product-focused vision hold immense promise to reshape the future of molecular detection. I look forward to working alongside Fred and the talented team to drive VedaBio’s innovative platform to market and help realize its full potential.'.

拉斯穆森博士说:“在这样一个关键时刻加入维达比奥,我很激动。”。我期待着与弗雷德和才华横溢的团队合作,推动韦达比奥的创新平台推向市场,并帮助实现其全部潜力。”。

About CRISPR Cascade™

关于CRISPR Cascade™

VedaBio’s CRISPR Cascade is a disruptive new molecular detection platform that operates with a combination of speed, accuracy and simplicity. The CRISPR Cascade platform eliminates the need for target amplification while maintaining high accuracy, all with a rapid analytical turnaround time. Unlike PCR or other DNA/RNA amplification technologies where assay design complexity significantly increases with multiplexing, the CRISPR Cascade removes several fundamental constraints, enabling incredibly simple, highly multiplexed assays without signal loss or cross reactivity issues, for example.

VedaBio的CRISPR Cascade是一个颠覆性的新型分子检测平台,它集速度,准确性和简单性于一体。CRISPR级联平台消除了目标扩增的需要,同时保持了高精度,所有这些都具有快速的分析周转时间。与PCR或其他DNA/RNA扩增技术不同,在PCR或其他DNA/RNA扩增技术中,检测设计的复杂性随着多路复用而显着增加,CRISPR级联消除了几个基本限制,从而实现了难以置信的简单,高度多路复用的检测,例如,没有信号丢失或交叉反应问题。

With performance that combines highly sensitive, accurate and rapid results, the CRISPR Cascade unlocks a universe of possibilities..

CRISPR Cascade的性能结合了高度灵敏,准确和快速的结果,开启了一个可能性的宇宙。。

About VedaBio

关于VedaBio

VedaBio is revolutionizing molecular biology with its breakthrough platform for ultra-rapid molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. Our CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries.

VedaBio凭借其突破性的多重分析物超快速分子检测平台正在彻底改变分子生物学,无需靶标扩增即可提供一流的准确性。我们的CRISPR Cascade™平台有望成为一种新的金标准工具,以增强跨多个行业的决策能力。

Learn more at vedabio.com..

更多信息,请访问vedabio.com。。